(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
2 July 2015 (02.07.2015)

WIPO | PCT

(10) International Publication Number
WO 2015/099989 A1

(51) International Patent Classification:
A61K 31/7072 (2006.01) *A61P 31/18* (2006.01)
C07H 19/10 (2006.01) *C07F 9/6558* (2006.01)

(21) International Application Number:
PCT/US2014/069123

(22) International Filing Date:
8 December 2014 (08.12.2014)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/920,371 23 December 2013 (23.12.2013) US

(71) Applicant: **GILEAD PHARMASSET LLC** [US/US]; C/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US).

(72) Inventors: **CASTEEL, Melissa, Jean**; C/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). **DASHNER, Kathleen**; C/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). **JUNG, Hyuk-jun**; C/o St Pharm, Co. Ltd., Shihwa, Industrial Complex, 1na-802, 231 Hyeomnyeok-ro, Shigeung-si, Gyeonggi-do, Gyeonggi-do 429-912 (KR). **SEO, Mun, Sik**; C/o St Pharm, Co. Ltd., Shihwa, Industrial Complex, 1na-802, 231 Hyeomnyeok-ro, Shigeung-si, Gyeonggi-do, Gyeonggi-do 429-912 (KR). **SHI, Bing**; C/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). **WANG, Fang**; C/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). **ZIA, Vahid**; C/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US).

(74) Agents: **ROZSNYAI, Lawrence F.** et al.; C/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,

[Continued on next page]

(54) Title: CRYSTALLINE FORMS OF ANTIVIRAL SOFOSBUVIR ANALOGUES

(57) Abstract: Crystalline solid forms of the anti-HCV compound (S)-isopropyl 2-((S)-(((2R,3R,4R,5R)- 5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-4-fluoro-3-hydroxy-4- methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate (Compound I) are described. Also provided are processes of making and methods of using the crystalline forms.





FIG 1



(I)

WO 2015/099989 A1

MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*